Insulet Corporation
Insulet Corporation Announces CTO Departure and Consulting Agreement
Summary
Insulet Corporation announced on March 14, 2025, the departure of Mark Field, its Senior Vice President and Chief Technology Officer, effective immediately. Subsequently, on April 7, 2025, the Company entered into a Consulting Services Agreement with Mr. Field, under which he will provide consulting services until August 31, 2025, for a fee of $450 per hour. His unvested equity will continue to vest during the consulting period.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement